Payment overview · 2025
General Payments
$1,336.31
71 reported records · 22 companies
Healthcare provider profile · identity verified
Crystal Easter Jones, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · NORTH WILKESBORO, NC · NPI 1275914285
Verified facts
What the public records show
CMS Open Payments records show Crystal Easter Jones, NP received $1,336.31 in general payments during 2025 across 71 reported records.
AstraZeneca Pharmaceuticals LP accounted for 20.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Ozempic, Trelegy Ellipta, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Viberzi by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $267.48 | 20.0% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $154.13 | 11.5% | 10 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $109.00 | 8.2% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $105.57 | 7.9% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $94.24 | 7.0% | 5 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $62.90 | 4.7% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $51.78 | 3.9% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $51.15 | 3.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $45.44 | 3.4% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $42.74 | 3.2% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.99 | 3.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $40.18 | 3.0% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $39.74 | 3.0% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $38.49 | 2.9% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $36.98 | 2.8% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $29.58 | 2.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.19 | 2.2% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $28.61 | 2.1% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $20.71 | 1.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.97 | 1.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.53 | 1.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.91 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,336.31 | 71 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $132.73 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $125.99 | 5 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $109.00 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $107.35 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $105.57 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $101.55 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $69.56 | 5 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $62.90 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $51.78 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $51.15 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $51.15 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $42.74 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $41.29 | 3 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $40.99 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $40.18 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $39.74 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $36.98 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $29.58 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.19 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $28.61 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $22.80 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $22.64 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $22.64 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $20.71 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.65 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.86 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.91 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $13.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 104 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 71 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 86 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 155 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 62 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
86 | 33 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
104 | 40 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
73 | 24 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
71 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
62 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
71 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
58 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
46 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
155 | 44 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
202 | 67 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 508 | 79 |
| Gabapentin | Gabapentin | 452 | 156 |
| Atorvastatin Calcium | Atorvastatin Calcium | 441 | 190 |
| Levothyroxine Sodium | Levothyroxine Sodium | 419 | 163 |
| Omeprazole | Omeprazole | 412 | 169 |
| Lisinopril | Lisinopril | 378 | 144 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 365 | 141 |
| Losartan Potassium | Losartan Potassium | 299 | 130 |
| Amlodipine Besylate | Amlodipine Besylate | 280 | 116 |
| Furosemide | Furosemide | 260 | 109 |
| Metformin Hcl | Metformin Hcl | 245 | 102 |
| Zolpidem Tartrate | Zolpidem Tartrate | 233 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 230 | 92 |
| Metoprolol Succinate | Metoprolol Succinate | 216 | 101 |
| Pantoprazole Sodium | Pantoprazole Sodium | 214 | 101 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 212 | 44 |
| Eliquis | Apixaban | 202 | 67 |
| Potassium Chloride | Potassium Chloride | 199 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 187 | 74 |
| Amoxicillin | Amoxicillin | 169 | 131 |
| Montelukast Sodium | Montelukast Sodium | 169 | 72 |
| Prednisone | Prednisone | 163 | 97 |
| Tramadol Hcl | Tramadol Hcl | 161 | 38 |
| Trazodone Hcl | Trazodone Hcl | 161 | 60 |
| Ozempic | Semaglutide | 155 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 152 | 69 |
| Pregabalin | Pregabalin | 151 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 148 | 62 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 141 | 66 |
| Lorazepam | Lorazepam | 141 | 24 |
| Simvastatin | Simvastatin | 129 | 54 |
| Clonazepam | Clonazepam | 128 | 25 |
| Buspirone Hcl | Buspirone Hcl | 127 | 51 |
| Ondansetron Odt | Ondansetron | 127 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 122 | 55 |
| Duloxetine Hcl | Duloxetine Hcl | 111 | 44 |
| Meloxicam | Meloxicam | 111 | 51 |
| Sertraline Hcl | Sertraline Hcl | 109 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 106 | 49 |
| Nystatin | Nystatin | 106 | 61 |
| Farxiga | Dapagliflozin Propanediol | 104 | 40 |
| Citalopram Hbr | Citalopram Hydrobromide | 100 | 32 |
| Fluconazole | Fluconazole | 95 | 59 |
| Glipizide | Glipizide | 95 | 38 |
| Ibuprofen | Ibuprofen | 93 | 36 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 92 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 89 | 36 |
| Ezetimibe | Ezetimibe | 86 | 40 |
| Linzess | Linaclotide | 86 | 33 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 84 | 72 |
| Ropinirole Hcl | Ropinirole Hcl | 82 | 32 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 79 | 32 |
| Famotidine | Famotidine | 78 | 29 |
| Ventolin Hfa | Albuterol Sulfate | 78 | 33 |
| Warfarin Sodium | Warfarin Sodium | 78 | 21 |
| Gemfibrozil | Gemfibrozil | 74 | 26 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 74 | 30 |
| Symbicort | Budesonide/Formoterol Fumarate | 73 | 24 |
| Allopurinol | Allopurinol | 72 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 36 |
| Jardiance | Empagliflozin | 71 | 25 |
| Metformin Hcl Er | Metformin Hcl | 69 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 69 | 22 |
| Temazepam | Temazepam | 64 | 12 |
| Lamotrigine | Lamotrigine | 63 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 62 | 21 |
| Azithromycin | Azithromycin | 60 | 56 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 22 |
| Atenolol | Atenolol | 58 | 23 |
| Mounjaro | Tirzepatide | 58 | 15 |
| Carvedilol | Carvedilol | 57 | 26 |
| Doxycycline Hyclate | Doxycycline Hyclate | 57 | 46 |
| Hydralazine Hcl | Hydralazine Hcl | 57 | 18 |
| Diazepam | Diazepam | 56 | 18 |
| Meclizine Hcl | Meclizine Hcl | 56 | 26 |
| Methylprednisolone | Methylprednisolone | 56 | 40 |
| Clobetasol Propionate | Clobetasol Propionate | 55 | 33 |
| Nitroglycerin | Nitroglycerin | 55 | 33 |
| Spironolactone | Spironolactone | 55 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 51 | 32 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 50 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 50 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 20 |
| Sucralfate | Sucralfate | 48 | 12 |
| Topiramate | Topiramate | 48 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 18 |
| Xarelto | Rivaroxaban | 47 | 17 |
| Trulicity | Dulaglutide | 46 | 14 |
| Levetiracetam | Levetiracetam | 45 | 15 |
| Promethazine Hcl | Promethazine Hcl | 45 | 20 |
| Glimepiride | Glimepiride | 43 | 22 |
| Propranolol Hcl | Propranolol Hcl | 43 | 14 |
| Risperidone | Risperidone | 43 | suppressed |
| Bupropion Xl | Bupropion Hcl | 41 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | 14 |
| Cephalexin | Cephalexin | 40 | 32 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 40 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | 20 |
| Valacyclovir | Valacyclovir Hcl | 39 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | 21 |
| Levofloxacin | Levofloxacin | 38 | 31 |
| Aripiprazole | Aripiprazole | 37 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 37 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 19 |
| Estradiol | Estradiol | 36 | 14 |
| Lovastatin | Lovastatin | 36 | 18 |
| Alendronate Sodium | Alendronate Sodium | 35 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 22 |
| Baclofen | Baclofen | 33 | 16 |
| Mirtazapine | Mirtazapine | 33 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 33 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 32 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 21 |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | 14 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 14 |
| Cefdinir | Cefdinir | 29 | 26 |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | 16 |
| Methocarbamol | Methocarbamol | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 29 | suppressed |
| Celecoxib | Celecoxib | 28 | 12 |
| Clonidine Hcl | Clonidine Hcl | 28 | 14 |
| Digoxin | Digoxin | 27 | 13 |
| Humalog Kwikpen U-100 | Insulin Lispro | 27 | 11 |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 13 |
| Repatha Sureclick | Evolocumab | 26 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Fenofibrate | Fenofibrate | 24 | 11 |
| Ofloxacin | Ofloxacin | 24 | 21 |
| Paliperidone Er | Paliperidone | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Metronidazole | Metronidazole | 22 | 13 |
| Belsomra | Suvorexant | 21 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 21 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 21 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Ssd | Silver Sulfadiazine | 20 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Carbamazepine Er | Carbamazepine | 17 | suppressed |
| Nystop | Nystatin | 17 | 12 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Modafinil | Modafinil | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Viberzi | Eluxadoline | 14 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Norethindrone | Norethindrone | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Sulindac | Sulindac | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Rufinamide | Rufinamide | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,336.31 · 71 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAPLYTA, CREON, Dexcom G6 Transmitter, ENTRESTO, FARXIGA, IBSRELA, JARDIANCE, Kerendia, LEQVIO, LINZESS, Leqembi, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, TRELEGY ELLIPTA, TRINTELLIX, VOQUEZNA, Wegovy, XHANCE, XIFAXAN, YUPELRI, ZAVZPRET, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error